Why the study?
Does aspirin reduce thromboembolic complications in patients over 40 undergoing total hip replacement?
Does aspirin reduce thromboembolic complications in patients over 40 undergoing total hip replacement?
Answers are grounded in this paper and cite their sources.
Aspirin prophylaxis appears to substantially reduce the risk of postoperative thromboembolism in high-risk patients undergoing total hip replacement.
A report by Harris and his associates in this issue of the Journal is of great interest and potential importance (p. 1246). Patients who underwent total hip replacement — a group at high risk for postoperative thromboembolism — were shown to benefit from prophylactic therapy with aspirin. Each subject was over the age of 40, had no prior history of thromboembolic disease or venous operations and received 600 mg of aspirin twice daily. Whereas a thromboembolic complication developed in 45 per cent of patients on placebo, only 25 per cent of those receiving aspirin acquired a deep vein thrombus as . . .
No takes yet. Share an insight, caveat, or question.
Aaron J. Marcus (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: